Norden Group’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.32M Buy
11,992
+2,732
+30% +$264K 0.1% 164
2026
Q2
$725K Sell
9,260
-368
-4% -$25.1K 0.06% 272
2026
Q1
$622K Sell
9,628
-2,062
-18% -$145K 0.06% 286
2025
Q4
$787K Sell
11,690
-550
-4% -$37K 0.08% 236
2025
Q3
$898K Sell
12,240
-3,721
-23% -$247K 0.09% 214
2025
Q2
$830K Sell
15,961
-3,457
-18% -$197K 0.09% 222
2025
Q1
$1.24M Sell
19,418
-8,583
-31% -$499K 0.14% 140
2024
Q4
$1.34M Sell
28,001
-516
-2% -$26.5K 0.15% 140
2024
Q3
$1.63M Buy
28,517
+11,944
+72% +$685K 0.19% 113
2024
Q2
$868K Buy
16,573
+3,757
+29% +$165K 0.18% 130
2024
Q1
$521K Buy
12,816
+4,091
+47% +$153K 0.11% 223
2023
Q4
$322K Buy
8,725
+3,090
+55% +$116K 0.06% 188
2023
Q3
$215K Hold
5,635
– – 0.07% 230

Other funds holding HALO

Norden Group's HALO Position: Q3 2026 in Review

Norden Group increased its Halozyme (HALO) stake by 30% in Q3 2026, buying an estimated $264K and bringing the position to 11,992 shares worth $1.32M. The position accounts for 0.1% of the portfolio, ranked #164.

Norden Group first reported a position in HALO in Q3 2023 and has held it in 13 quarters since. The position peaked at $1.63M in Q3 2024. 777 funds tracked by Wall St. Rank hold HALO as of Q3 2026.

  • Norden Group held 11,992 shares of Halozyme worth $1.32M as of Q3 2026.
  • Norden Group bought 2,732 Halozyme shares in Q3 2026, an estimated $264K.
  • Halozyme made up 0.1% of Norden Group's portfolio in Q3 2026, its #164 holding.
  • Norden Group first reported a position in Halozyme in Q3 2023 and has held it in 13 quarters since.
  • Norden Group's Halozyme position peaked at $1.63M in Q3 2024.
  • 777 funds tracked by Wall St. Rank held Halozyme as of Q3 2026.

Based on Norden Group's 13F filing for Q3 2026, filed 20 Oct 2026.